Journal Article Summary
The article presents the annual report for the Toxicology Investigators Consortium (ToxIC) for 2021, which is a registry established to collect data on medical toxicology consultations. This registry is significant as it helps track trends in toxic exposures and the effectiveness of treatments, which is crucial for improving patient care and public health responses, especially in the context of increasing substance misuse and the ongoing opioid crisis. The report highlights the growing number of cases and the types of substances involved, providing valuable insights into the landscape of toxicological emergencies.
In 2021, the ToxIC Core Registry recorded 8,552 cases from 34 sites across 55 healthcare facilities, marking a 28% increase from the previous year. The data collected included patient demographics, reasons for consultations, types of substances involved, clinical symptoms, and outcomes. Notably, non-opioid analgesics were the most frequently reported substances, followed closely by opioids, with fentanyl being the leading opioid associated with fatalities. The report also examined new demographic variables and the impact of the COVID-19 pandemic on toxic exposures, revealing that intentional pharmaceutical exposures were the most common reason for consultations, often linked to self-harm.
Despite its comprehensive data collection, the report acknowledges several limitations, including potential biases in case selection and reporting, as only more severe cases that required specialist consultation are included. This could lead to an underrepresentation of less severe cases typically seen in other databases, such as those maintained by Poison Centers. Patients and caregivers should discuss any concerns about toxic exposures or substance use with healthcare professionals, as they can provide guidance tailored to individual circumstances and help navigate the complexities of treatment and prevention.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Love Jennifer S., Karshenas Dana L., Spyres Meghan B., Farrugia Lynn A., Kang A. Min, Nguyen HoanVu, Campleman Sharan L., Li Shao, et al.. The Toxicology Investigators Consortium Case Registry—the 2021 Annual Report. Journal of Medical Toxicology 2022. DOI: 10.1007/s13181-022-00910-6. PMID: 36070069. PMCID: PMC9450833.
Featured Pill Pals Product
Cyclobenzaprine 5 mg Tablets --- Generic For Flexeril --- TruPharma
Cyclobenzaprine 5 mg Tablets — Generic For Flexeril — TruPharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
